Results 231 to 240 of about 326,708 (370)

KRAS mRNA Spleen‐Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
To overcome pancreatic cancer's immunosuppressive barriers, this study explores a dual approach: triggering immunogenic tumor cell death at the primary tumor site with irinotecan‐loaded silicasomes and enhancing immune activation in the spleen using LNPs encapsulating tumor antigen mRNA and a TLR7/8 agonist.
Lijia Luo   +3 more
wiley   +1 more source

Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas [PDF]

open access: bronze, 2006
John M. Pagel   +8 more
openalex   +1 more source

Tumor Small Extracellular Vesicle‐Transmitted LncRNA CATED Promotes Platinum‐Resistance in High‐Grade Serous Ovarian Cancer

open access: yesAdvanced Science, EarlyView.
Overcoming platinum resistance in high‐grade serous ovarian cancer (HGSOC) is critical for improving outcomes. This study identifies lncRNA CATED, elevated in platinum‐resistant small extracellular vesicles (sEVs) and tumors, which drives cisplatin resistance by enhancing DHX36 SUMOylation, boosting RAP1A translation, and activating MAPK signaling ...
Yi Liu   +7 more
wiley   +1 more source

Development of a DNA Aptamer‐Based Approach to Noninvasively Image CAR‐T Cells In Vivo and Traceless Enrichment In Vitro

open access: yesAdvanced Science, EarlyView.
A DNA aptamer (A3) with nanomolar affinity for CAR‐T cells is developed via Cell‐SELEX. In Nalm6 tumor‐bearing mice, Cy5‐labeled A3 enables long‐term fluorescence imaging and tracks the biodistribution of CAR‐T cells, with tumor signal peaking on day 14 after CAR‐T cell administration.
Minghui Chen   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy